期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

7种血管紧张肽Ⅱ受体1拮抗药降压疗效比较 被引量：3

Comparison of antihypertensive efficacy of 7 angiotensin Ⅱ receptor 1 antagonist
原文传递
导出
摘要 血管紧张肽Ⅱ受体1拮抗药(ARB)是一类第一线的降压药物,具有疗效显著、不良反应轻等优点。本文根据已发表的文章,对7种ARB在起始剂量和推荐剂量下的降压疗效进行比较。研究表明,奥美沙坦、替米沙坦等t1/2较长的ARB具有较强的降压作用。 Agiotensin Ⅱ receptor 1 antagonist is a first-line antihypertensive agent, and has the advantage of good efficacy and less adverse reaction. According to the published paper, the antihypertensive efficacy of 7 angiotensin Ⅱ receptor 1 antagonists in starting dosage and recommended dosage was compared in this paper. Some studies showed that some newer, longer half-life angiotensin Ⅱ reeeptor 1 antagonist （such as olmesartan and telmisartan） had stronger antihypertensive effieacy.
作者 黄震华
机构地区 上海交通大学医学院附属第九人民医院心血管病研究室
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2009年第11期810-813,共4页 Chinese Journal of New Drugs and Clinical Remedies
关键词 高血压 血管紧张素类 受体 血管紧张素 抗高血压药 hypertension angiotensins receptors, angiotensin antihypertensive agents
分类号 R544.1 [医药卫生—心血管疾病] R972.4 [医药卫生—药品]
  • 相关文献

参考文献17

  • 1ANDERSSON OK, NELDAM S. The antihypertensive effect and tolerability of candesartan eilexetil, a new generation angiotensin Ⅱ antagonist, in comparison with losartan[J]. Blood Press, 1998, 7(1): 53-59.
  • 2BAKRIS G, GRADMAN A, REIF M, et al. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study[J]. J Clin Hypertens, 2001, 3(1): 16-21.
  • 3BRUNNER HR, STUMPE KO, JANUSZEWICZ A. Antihyperteusive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension [J]. Clin Drug Investig, 2003, 23(7): 419-430.
  • 4BALL KJ, WILLIAMS PA, STUMPE KO. Relative efficacy of an angiotensin Ⅱ antagonist compared with other antihypertensive agents: ohnesartan medoxomil versus antihypertensives[J]. J Hypertens Suppl, 2001, 19(1): S49-S56.
  • 5GILES TD, OPARIL S, SILFANI TN, et ol. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension [J]. J Clin Hypertens, 2007, 9(3): 187-195.
  • 6OPARIL S, WILLIAMS D, CHRYSANT SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension[J]. J Clin Hypertens, 2001, 3 (5): 283-318.
  • 7DEROSA G, RAGONESI PD, MUGELLINI A, et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebocontrolled 12 month study[J]. Hypertens Res, 2004, 27 (7): 457-464.
  • 8SMITH DH. Comparison of angiotensin Ⅱ type 1 receptor antagonists in the treatment of essential hypertension [J]. Drugs, 2008, 68(9): 1207-1225.
  • 9LITTLEJOHN T, MROCZEK W, MARBURY T, et al. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring[J]. Can J Cardiol, 2000, 16(9): 1123-1132.
  • 10ELLIOTT WJ, CALHOUN DA, DELUCCA PT, et al. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial[J]. Clin Ther, 2001, 23(8): 1166-1179.

同被引文献32

引证文献3

二级引证文献15

中国新药与临床杂志
2009年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部